ciglitazone has been researched along with Malignant Melanoma in 7 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We have previously demonstrated that the thiazolidinedione ciglitazone inhibited, independently of PPARγ activation, melanoma cell growth." | 7.77 | Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth. ( Ballotti, R; Bertolotto, C; Botton, T; Cheli, Y; Deckert, M; Fajas, L; Giuliano, S; Ortonne, JP; Puissant, A; Rocchi, S; Tartare-Deckert, S; Tomic, T, 2011) |
| " In this report, focusing our attention on ciglitazone, we show that ciglitazone inhibits melanoma growth by inducing apoptosis and cell-cycle arrest, whereas normal melanocytes are resistant to ciglitazone." | 7.75 | In vitro and in vivo anti-melanoma effects of ciglitazone. ( Annicotte, JS; Bahadoran, P; Ballotti, R; Bertolotto, C; Botton, T; Fajas, L; Gozzerino, G; Ortonne, JP; Puissant, A; Rocchi, S; Tartare-Deckert, S; Zamoum, T, 2009) |
| "We have previously demonstrated that the thiazolidinedione ciglitazone inhibited, independently of PPARγ activation, melanoma cell growth." | 3.77 | Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth. ( Ballotti, R; Bertolotto, C; Botton, T; Cheli, Y; Deckert, M; Fajas, L; Giuliano, S; Ortonne, JP; Puissant, A; Rocchi, S; Tartare-Deckert, S; Tomic, T, 2011) |
| " In this report, focusing our attention on ciglitazone, we show that ciglitazone inhibits melanoma growth by inducing apoptosis and cell-cycle arrest, whereas normal melanocytes are resistant to ciglitazone." | 3.75 | In vitro and in vivo anti-melanoma effects of ciglitazone. ( Annicotte, JS; Bahadoran, P; Ballotti, R; Bertolotto, C; Botton, T; Fajas, L; Gozzerino, G; Ortonne, JP; Puissant, A; Rocchi, S; Tartare-Deckert, S; Zamoum, T, 2009) |
| "The PPAR-gamma ligands, 15-deoxy-Delta(12,14)-prostaglandin J(2) and ciglitazone, and the PPAR-alpha ligand, WY-14643, were examined for their effects on proliferation and apoptosis of A375 melanoma, DU145 and PC3 prostate cancer, and MB-MDA-231 breast cancer." | 3.73 | PPAR-gamma ligands and amino acid deprivation promote apoptosis of melanoma, prostate, and breast cancer cells. ( Liu, H; Meadows, GG; Núñez, NP, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Botton, T | 2 |
| Puissant, A | 2 |
| Bahadoran, P | 1 |
| Annicotte, JS | 1 |
| Fajas, L | 2 |
| Ortonne, JP | 2 |
| Gozzerino, G | 1 |
| Zamoum, T | 1 |
| Tartare-Deckert, S | 2 |
| Bertolotto, C | 2 |
| Ballotti, R | 2 |
| Rocchi, S | 2 |
| Schadendorf, D | 1 |
| Cheli, Y | 1 |
| Tomic, T | 1 |
| Giuliano, S | 1 |
| Deckert, M | 1 |
| Paulitschke, V | 1 |
| Gruber, S | 1 |
| Hofstätter, E | 1 |
| Haudek-Prinz, V | 1 |
| Klepeisz, P | 1 |
| Schicher, N | 1 |
| Jonak, C | 1 |
| Petzelbauer, P | 1 |
| Pehamberger, H | 1 |
| Gerner, C | 1 |
| Kunstfeld, R | 1 |
| Placha, W | 2 |
| Gil, D | 1 |
| Dembińska-Kieć, A | 1 |
| Laidler, P | 2 |
| Núñez, NP | 1 |
| Liu, H | 1 |
| Meadows, GG | 1 |
| Grabacka, M | 1 |
| Urbanska, K | 1 |
| Płonka, PM | 1 |
| Reiss, K | 1 |
7 other studies available for ciglitazone and Malignant Melanoma
| Article | Year |
|---|---|
In vitro and in vivo anti-melanoma effects of ciglitazone.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Re | 2009 |
Peroxisome proliferator-activating receptors: a new way to treat melanoma?
Topics: Antineoplastic Agents; Apoptosis; Humans; Melanoma; PPAR gamma; Signal Transduction; Skin Neoplasms; | 2009 |
Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Line, Tumor; Chemokine CXCL1; | 2011 |
Proteome analysis identified the PPARγ ligand 15d-PGJ2 as a novel drug inhibiting melanoma progression and interfering with tumor-stroma interaction.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chromans; Hu | 2012 |
The effect of PPARgamma ligands on the proliferation and apoptosis of human melanoma cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Division; Cell Line, Tumor; DNA; Dose-Resp | 2003 |
PPAR-gamma ligands and amino acid deprivation promote apoptosis of melanoma, prostate, and breast cancer cells.
Topics: Amino Acids; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferatio | 2006 |
PPAR gamma regulates MITF and beta-catenin expression and promotes a differentiated phenotype in mouse melanoma S91.
Topics: Alitretinoin; Animals; Antigens, Differentiation; Antineoplastic Agents; beta Catenin; Blotting, Wes | 2008 |